Regulatory considerations for NK cells used in human immunotherapy applications

Methods in Molecular Biology

Volumn 1441, Issue , 2016, Pages 347-361

  Lee, Dean A ^a  

^a NONE

Author keywords

Certificate of analysis; Clinical trials; Good manufacturing practice; NK cell adoptive immunotherapy; Release criteria

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; CERTIFICATION; CRYOPRESERVATION; FEEDER CELL; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HUMAN; NATURAL KILLER CELL; PRODUCT SAFETY; CELL CULTURE TECHNIQUE; CYTOLOGY; LEGISLATION AND JURISPRUDENCE; PROTOCOL COMPLIANCE; STANDARDS; TRANSPLANTATION;

CELL CULTURE TECHNIQUES; GUIDELINE ADHERENCE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL;

EID: 84979266066     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3684-7_29     Document Type: Chapter

References (28)

1. Facts About the Current Good Manufacturing Practices (CGMPs) (2005) U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm. Accessed 4 Nov 2015
2. Good-manufacturing-practice and gooddistribution- practice compliance (2015) European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000154.jsp. Accessed 4 Nov 2015
3. Biologicals: Good Manufacturing Practices (2015) World Health Organization, http://www.who.int/biologicals/vaccines/good_manufacturing_practice/en/. Accessed 4 Nov 2015
4. Guidance for Industry: CGMP for Phase 1 Investigational Drugs (2008) http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070273.pdf
5. Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well- Characterized, Therapeutic, Biotechnology- derived Products (1995) http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071597.pdf
6. Guidance for Industry: Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information (2012) http://www.fda.gov/downloads/BiologicsBloodVaccines/Guidance-ComplianceRegulatoryInformation/Guidances/General/UCM292704.pdf
7. Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Control (CMC) Reviewers of Human Somatic Cell Therapy Investigational New Drug Applications (INDs) (2003) http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm074131.htm
8. Siegler U, Meyer-Monard S, Jorger S et al (2010) Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR- positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 12:750-763
9. Boissel L, Tuncer HH, Betancur M et al (2008) Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 14:1031-1038
10. Berg M, Lundqvist A, McCoy P Jr et al (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341-355
11. North J, Bakhsh I, Marden C et al (2007) Tumor- primed human natural killer cells lyse NK-resistant tumor targets: evidence of a twostage process in resting NK cell activation. J Immunol 178:85-94
12. Harada H, Watanabe S, Saijo K et al (2004) A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol 32:614-621
13. Fujisaki H, Kakuda H, Shimasaki N et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010-4017
14. Denman CJ, Senyukov VV, Somanchi SS et al (2012) Membrane-bound IL-21 promotes sustained Ex vivo proliferation of human natural killer cells. PLoS One 7, e30264
15. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993) http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/ucm162863.pdf
16. Medicinal and other products and human and animal transmissible spongiform encephalopathies: memorandum from a WHO meeting (1997). Bull World Health Organ 75:505-513
17. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3) (2011) (European Commission, ed), Official Journal of the European Union http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf
18. Bovine Spongiform Encephalopathy (BSE) Questions and Answers (2015) http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm111482.htm
19. Sundin M, Ringden O, Sundberg B et al (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92:1208-1215
20. Coecke S, Balls M, Bowe G et al (2005) Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice. Altern Lab Anim 33:261-287
21. Lapteva N, Szmania SM, van Rhee F et al (2014) Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog 19:121-132
22. Marti F, Miralles A, Peiro M et al (1993) Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities. Transfusion 33:651-655
23. Martelli MF, Aversa F, Bachar-Lustig E et al (2002) Transplants across human leukocyte antigen barriers. Semin Hematol 39:48-56
24. Miller JS (2013) Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program 2013:247-253
25. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products (2011) (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), ed)
26. Somanchi SS, McCulley KJ, Somanchi A et al (2015) A novel method for assessment of natural killer cell cytotoxicity using image cytometry. PLoS One 10, e0141074
27. Romain G, Senyukov V, Rey-Villamizar N et al (2014) Antibody Fc-engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 124(22):3241-3249
28. Hurton LV, Siddik RI, Singh H et al (2010) Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24:1059-1062